San Diego-based Lpath Inc. (Nasdaq: LPTN) received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a $1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab.
Lpathomab is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).
The Phase 1 amount of $224,000 will fund studies designed to repeat in rats the efficacy previously demonstrated (several times in mice) in a controlled-cortical-impact model of TBI. Contingent on Phase 1 success, Phase 2 funds of almost $1.5 million will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND.
The National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Fast Track Program was created to provide grants to accelerate the transition from development stage to commercialization of innovative technologies that improve human health and advance the mission of the NIH.
The program also aims to foster partnerships among a variety of R&D collaborators working toward these goals. To this end, Lpath has partnered this project with the UCLA Department of Neurosurgery and its prestigious Brain Injury Research Center with Neil Harris, Ph.D., as a co-principal investigator on the project.